A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to Gram-Positive Organisms

Trial Profile

A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to Gram-Positive Organisms

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Dalbavancin (Primary) ; Cefazolin; Nafcillin; Oxacillin; Vancomycin
  • Indications Bacterial infections; Osteomyelitis
  • Focus Therapeutic Use
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 15 Jun 2016 The trial was prematurely ended in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top